MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Biocomposites Teams Up with Zimmer Biomet to Offer New Bone Graft Substitute in the U.S.

Image courtesy of Biocomposites genex Bone Graft Substitute syringe and beads-web.jpg
The U.K.-based company has devised new mixing and delivery systems for the U.S. orthopedic market to save time and meet surgeon preferences.

Keele, UK-based Biocomposites has reached a multi-year agreement with Zimmer Biomet to exclusively distribute genex Bone Graft Substitute in the United States with a new mixing system and new delivery options. genex has been updated for the U.S market to include a new closed-mixing system that could shorten preparation time and extend working time. The new bone graft substitute will also be provided with a more comprehensive set of delivery options to allow a surgeon to inject, mold, or prepare beads in accordance with their chosen technique, Biocomposites reported in a news release.

“I am delighted we are partnering with Zimmer Biomet to deliver our new genex Bone Graft Substitute product to the U.S. market,” shared Michael Harris, Chief Executive Officer of Biocomposites, in a news release. “genex is already used and valued by surgeons in over 30 countries, including the US, undertaking 15,000 cases each year. The upgraded offering which we are providing to Zimmer Biomet will further benefit many more physicians and patients across the U.S.”

Added Brian Hatcher, President of Zimmer Biomet’s CMFT, Foot & Ankle and Trauma: “We are excited to partner with Biocomposites to bring the new genex Bone Graft Substitute kits to surgeons as we continue to advance our mission to alleviate pain and improve the quality of life for people around the world.”

The company explained that genex Bone Graft Substitute consists of a 50:50 biphasic composition of calcium sulfate and β-tricalcium phosphate developed to balance osteoconductive scaffold strength and persistence in the body to enable the optimal remodelling of bone architecture.1 It also has a negatively charged surface chemistry that has demonstrated a favourable osteogenic bone growth response up to five times normal (positively charged) levels, InVitro.2 In addition, the proprietary recrystallization and purification production methods give genex its distinct properties and removes slow and non-absorbing compounds, such as hydroxyapatite, to ensure that it is completely absorbed and remodelled within 12 months.3

References

  1. Yang HL et al. "Bone healing response to a synthetic calcium sulfate/β-tricalcium phosphate graft material in a sheep vertebral body defect model," J Biomed Mater Res B Appl Biomater 2012;100B(7):1911–21.
  2. Cooper JJ et al. "Enhancing the osteogenic potential of bioabsorbable implants through control of surface charge," Presented at the Society for Biomaterials 2007 Annual Meeting, April 2007: Chicago, Illinois, USA. Laboratory studies are not necessarily indicative of clinical result.
  3. Clinical case study: Mr A Nisar and Mr S Gopal; Proximal femur fracture, Data on file.

 

Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish